MAPRx

MAPRx Therapeutics is a preclinical-stage biotechnology company focused on developing novel small molecule therapies for neurodegenerative diseases, with a primary emphasis on targeting the microtubule-associated protein tau (MAPT). The company aims to address the underlying pathology of Alzheimer's disease and other tauopathies by modulating tau protein to prevent its toxic accumulation and spread in the brain. Founded and backed by Apple Tree Partners (ATP), MAPRx leverages deep expertise in neuroscience and protein homeostasis to advance its proprietary discovery platform. The company's approach targets the 'MAP' (Microtubule-Associated Protein) to halt or reverse cognitive and functional decline in patients. MAPRx is headquartered in Cambridge, Massachusetts, and is led by a team of experienced drug hunters and neuroscientists.